Year-end Sale % OFF 
Abstract
e14545 Background: Gemcitabine based chemotherapy has become the standard of care for first-line treatment of patients with advanced pancreatic cancer. However, median survival remains disappointing. Continuous infusion 5-fluorouracil (5 FU), calcium leucovorin plus paclitaxel and oxaliplatin has shown activity in patients with pancreatic cancer. As a protracted low dose infusion, 5FU is antiangiogenic and potentiates bevacizumab as observed in the treatment of colon cancer. When combined with bevacizumab, nab-paclitaxel is also synergetic because of its antiangiogenic properties. We administered low doses of continuous cytotoxic chemotherapy with conventional anti-VEGF therapy for patients with advanced pancreatic cancer. Methods: Since July of 2008 we treated 28 patients with 5 FU (180 mg/m2/d) as a continuous infusion on days 1-15 via ambulatory chemotherapy pump into a surgically placed central venous line. Calcium leucovorin (20 mg/m2) IVP, nab-paclitaxel (100 mg/m2) IV as a 30 minute infusion and ox...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
